Bolt Biotherapeutics, Inc. (BOLT) stock
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 11/3034% below fair value
$5.91−0.35 (-5.59%)
Close on Nov 12, 2026Market cap $11.38MP/E –Yield –
Bolt Biotherapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Bolt Biotherapeutics's enterprise value was -$6.04M on Nov 11, 2026, against -$29.07M a year earlier. Over the last 5 years it ranged from -$160.64M to -$5.41M, with a median of -$72.70M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$6.04M | – |
| 2025 | Dec 31, 2025 | -$28.30M | – |
| 2024 | Dec 31, 2024 | -$63.92M | – |
| 2023 | Dec 29, 2023 | -$98.88M | – |
| 2022 | Dec 30, 2022 | -$160.64M | – |
| 2021 | Dec 31, 2021 | -$30.38M | – |
See a number that looks wrong?